Patent intelligence · US
US 11911345
Phage dispensing system
Phage dispensing system
Patent details — US 11911345
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 27, 2024
- Expiration
- Feb 22, 2044
- Applicant
- Adaptive Phage Therapeutics, Inc.
- Claims
- 28
- CPC classes
- A61K, A61K35/76
Quick answer
US 11911345 (Phage dispensing system) is held by Adaptive Phage Therapeutics, Inc.. Status: granted. Granted Feb 27, 2024. Expires Feb 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Adaptive Phage Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K35/76
More from Adaptive Phage Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12264187
Compositions and methods for targeted therapeutic delivery to bone
granted -
US 12263179
Lyme disease-associated T cell receptor-related methods
granted -
US 12266425
T cell receptor sequences diagnostic for COVID-19 and related compositions
granted -
US 12006517
Method for purification of bacteriophage particles
granted -
US 11773138
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted -
US 11390921
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
granted -
US 11192923
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted
Frequently asked questions
What is US patent 11911345?
US 11911345 (Phage dispensing system) is held by Adaptive Phage Therapeutics, Inc.. Status: granted. Granted Feb 27, 2024. Expires Feb 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11911345?
Adaptive Phage Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 11911345 expire?
Our index shows an expiration date of Feb 22, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.